Mumbai, India, November 14th, 2025: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended September 30, 2025.
Financial and Business Summary for Q2FY26
- Revenue from Operations of Q2FY26 stood at INR 12,970 Mn, a growth of 34% YoY across regions
- Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/ CDMO contribute 74%, 13%, 10% and 2% of revenue from operations respectively for Q2FY26.
- ROCE is at 16.2% (Post Acquisition of Senn Chemicals AG) as compared to 16.9% YoY.
- Net debt stood at INR 10,241 Mn and Net debt to EBITDA at 0.98x.
Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “We are delighted to deliver a resilient financial performance with healthy growth in both revenue and profitability. The improvement in EBITDA and PAT reflects our continued focus on operational excellence, disciplined execution, and the strength of our governance. Our ongoing investments in R&D and talent underscore our commitment to innovation and long-term value creation. Our peptides CDMO platform through Ascelis, anchored in the legacy of Senn Chemicals in Switzerland, is steadily gaining visibility, with renewed customer interest and promising new discussions underway.”